121 related articles for article (PubMed ID: 30357450)
1. Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Arora P; Adams CH; Gudelsky G; DasGupta B; Desai PB
Cancer Chemother Pharmacol; 2019 Jan; 83(1):81-89. PubMed ID: 30357450
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis.
Dave N; Gudelsky GA; Desai PB
Cancer Chemother Pharmacol; 2013 Aug; 72(2):349-57. PubMed ID: 23748921
[TBL] [Abstract][Full Text] [Related]
3. Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights.
Arora P; Gudelsky G; Desai PB
PLoS One; 2021; 16(4):e0248579. PubMed ID: 33798227
[TBL] [Abstract][Full Text] [Related]
4. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis.
Apparaju SK; Gudelsky GA; Desai PB
Cancer Chemother Pharmacol; 2008 Feb; 61(2):223-9. PubMed ID: 17443325
[TBL] [Abstract][Full Text] [Related]
6. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Res; 1996 May; 56(9):1983-7. PubMed ID: 8616836
[TBL] [Abstract][Full Text] [Related]
7. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
[TBL] [Abstract][Full Text] [Related]
8. TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Zhuang D; Liu Y; Mao Y; Gao L; Zhang H; Luan S; Huang F; Li Q
Int J Cancer; 2012 Jan; 130(2):309-18. PubMed ID: 21328340
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Zhou Q; Guo P; Wang X; Nuthalapati S; Gallo JM
J Pharmacol Exp Ther; 2007 Apr; 321(1):265-75. PubMed ID: 17259446
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Zhou Q; Gallo JM
Neuro Oncol; 2009 Jun; 11(3):301-10. PubMed ID: 18971416
[TBL] [Abstract][Full Text] [Related]
11. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Rosso L; Brock CS; Gallo JM; Saleem A; Price PM; Turkheimer FE; Aboagye EO
Cancer Res; 2009 Jan; 69(1):120-7. PubMed ID: 19117994
[TBL] [Abstract][Full Text] [Related]
12. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S; Ahsan SM; Kumar JM; Kondapi AK; Rao NM
Sci Rep; 2017 Jul; 7(1):6602. PubMed ID: 28747713
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
[TBL] [Abstract][Full Text] [Related]
14. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
15. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Riva M; Wouters R; Sterpin E; Giovannoni R; Boon L; Himmelreich U; Gsell W; Van Ranst M; Coosemans A
Neurosurgery; 2021 Jan; 88(2):E205-E215. PubMed ID: 33289503
[TBL] [Abstract][Full Text] [Related]
17. Triolein emulsion enhances temozolomide brain delivery: an experimental study in rats.
Seung WB; Cha SH; Kim HJ; Choi SH; Lee J; Kwak D; Hyun Woo K; You JW; Kim YW; Kim SK; Lee DS
Drug Deliv; 2021 Dec; 28(1):2373-2382. PubMed ID: 34747271
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Ma J; Li S; Reed K; Guo P; Gallo JM
J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
[TBL] [Abstract][Full Text] [Related]
20. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Tentori L; Leonetti C; Scarsella M; Vergati M; Xu W; Calvin D; Morgan L; Tang Z; Woznizk K; Alemu C; Hoover R; Lapidus R; Zhang J; Graziani G
Int J Oncol; 2005 Feb; 26(2):415-22. PubMed ID: 15645126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
